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Abstract: Osteoarthritis is common in patients $65 years of age. Although nonsteroidal 
  anti-inflammatory drugs (NSAIDs) are often prescribed for osteoarthritis pain, they pose age-
related cardiovascular, renal, and gastrointestinal risks. Two topical NSAIDs, diclofenac sodium 
1% gel (DSG) and diclofenac sodium 1.5% in 45.5% dimethylsulfoxide solution (D-DMSO), 
are approved in the US for the treatment of osteoarthritis pain. Topical NSAIDs have shown 
efficacy and safety in knee (DSG, D-DMSO) and hand (DSG) osteoarthritis. Analyses of data 
from randomized controlled trials of DSG in hand and knee osteoarthritis demonstrate signifi-
cant improvement of pain and function in both younger patients (,65 years) and older patients 
($65 years) and suggest good safety and tolerability. However, long-term safety data in older 
patients are limited. Topical NSAIDs can ease medication administration and help address 
  barriers to pain management in older patients, such as taking multiple medications and inability 
to swallow, and are a valuable option for long-term care providers.
Keywords: nonsteroidal anti-inflammatory drugs, long-term care, nursing homes, chronic 
pain, topical analgesics
Introduction
Osteoarthritis affects many older persons aged $65 years. Knee osteoarthritis occurs in 
more than 32% of these individuals,1 and hand osteoarthritis occurs in more than 50% 
of older patients.2 A multitude of treatment modalities are available for patients with 
osteoarthritis, among which a balance between efficacy, safety, and convenience must 
be found to achieve successful long-term management of symptoms. An algorithm has 
been proposed as an aid to navigating the clinical options (see Figure 1).3
Treatment of osteoarthritis begins with education of patients about the disease 
and nonpharmacological interventions to minimize pain and improve function. These 
include measures such as exercise to improve strength and range of motion, pac-
ing of activities, weight reduction, use of braces or splints, application of heat, and 
acupuncture.4,5 However, the treatment of osteoarthritis typically requires a combination 
of nonpharmacologic and pharmacologic interventions.
For patients in need of pharmacotherapy, acetaminophen (paracetamol) is among 
the mainstays of pharmacologic agents that rapidly relieve symptoms and is recom-
mended as first-line therapy by most osteoarthritis treatment guidelines.4,5 Other orally 
administered drugs, such as tramadol, opioids, selective serotonin reuptake inhibitors, 
and serotonin-norepinephrine reuptake inhibitors are used as second-line treatment 
or adjunctively. Topically applied products are usually also indicated as second-line 
agents, some of which (eg, salicylates and the lidocaine 5% patch) are available only Therapeutics and Clinical Risk Management 2011:7
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Figure 1 Treatment algorithm for symptomatic osteoarthritis. 
Abbreviations: COX-2, cyclo-oxygenase-2; iv, intravenous; NSAiD, nonsteroidal 
anti-inflammatory drug; PGE2, prostaglandin e2; PPi, proton pump inhibitor; PO, 
oral; SNRi, selective norepinephrine reuptake inhibitor; SSRi, selective serotonin 
reuptake inhibitor.
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in a topical form. Although frequently prescribed for osteoar-
thritis pain, it should be noted that the lidocaine 5% patch is 
approved in the US only for postherpetic neuralgia.6 Some 
guidelines give topical treatments precedence over systemic 
treatments for patients with osteoarthritis of the hand.4
Nonsteroidal anti-inflammatory drugs (NSAIDs) are also 
frequently prescribed for osteoarthritis pain, but have age-
related risks of cardiovascular,7 renal,8 and gastrointestinal 
adverse events.9 To minimize risks, treatment guidelines for 
chronic pain4,5,10–12 recommend rare and cautious use of oral 
NSAIDs in the elderly. Guidelines4,5,13 also suggest limiting 
NSAID exposure by prescribing the lowest effective dose for 
the shortest possible duration, typically with a gastroprotec-
tive agent, such as a proton pump inhibitor, or misoprostol, 
prostaglandin E1 analog. A recent review concluded that 
NSAIDs are appropriate for use in older patients, as long 
as medical history, comorbid conditions, and concomitant 
medications are taken into consideration.
Topical NSAIDs may limit NSAID exposure by acting 
locally with less systemic distribution. Two topical NSAIDs 
are approved in the US for treating osteoarthritis pain, ie, 
diclofenac sodium 1% gel (DSG, Voltaren® Gel, Endo Phar-
maceuticals Inc, Chadds Ford, PA) and diclofenac sodium 
1.5% in 45.5% dimethylsulfoxide solution (D-DMSO, 
Pennsaid®, Mallinckrodt Pharmaceuticals Inc, Hazelwood, 
MO). Topical diclofenac is effectively absorbed in the knee14 
and hand;15 however, plasma concentrations remain very 
low. Clinical trial data support the efficacy and safety of 
DSG16,17 and D-DMSO18,19 in patients with knee osteoarthritis 
and DSG in hand osteoarthritis.20 Effect sizes calculated for 
DSG and D-DMSO indicate that the two topical diclofenac 
formulations show efficacy similar to that of oral NSAIDs.21 
A recent review has summarized and compared clinical study 
data on the various available topical NSAID products as 
tested in general populations of patients with knee or hand 
osteoarthritis.22
It is the purpose of this article to briefly review clinical 
data on topical NSAIDs for osteoarthritis pain in older and 
younger patients. Safety and efficacy results, irrespective of 
age, and the role of topical NSAIDs in long-term care will 
be discussed.
Age-related NSAID risks
NSAIDS, particularly cyclo-oxygenase-2 inhibitors, are asso-
ciated with an increased risk of cardiovascular adverse events7 
and clinically meaningful increases in blood   pressure.23 
Because cardiovascular disease increases with age,24 older 
patients are particularly susceptible to these events.7 Simi-
larly, NSAIDs are more likely to cause renal adverse events in 
older patients.8 Moreover, acid-related disorders (ie, ulcers) 
increase with age,25 and epidemiologic studies suggest that 
approximately 90% of patients with osteoarthritis have 
an increased risk of gastrointestinal bleeding.26 Although 
cyclo-oxygenase-2 inhibitors were developed to minimize 
gastrointestinal risk, population-based studies provide lim-
ited support for improved tolerability.9 For topical NSAID 
formulations with DMSO, which is both a solvent and an 
enhancer of dermal penetration,27 age-related skin changes 
could in theory increase NSAID absorption, although no data 
are available to confirm or refute this hypothesis. However, 
the penetration-enhancing effects of DMSO are maximized 
only at concentrations .60%,27 which is greater than the 
45.5% concentration in D-DMSO.
Older patients with osteoarthritis are likely to have 
comorbidities requiring medications that may adversely 
interact with some osteoarthritis pharmacotherapies.28 
Warfarin treatment in patients taking NSAIDs increases 
bleeding risk.29 Selective serotonin reuptake inhibitors, 
serotonin-norepinephrine reuptake inhibitors, and corticos-
teroids can also increase bleeding risk.11 Antihypertensives 
lose effectiveness when administered with certain NSAIDs,30 
and ibuprofen may neutralize the cardioprotective effects of 
low-dose aspirin.31 Proton pump inhibitors (administered 
for gastroprotection during NSAID therapy) can neutralize 
the therapeutic effects of clopidogrel, increasing the risk of 
myocardial infarction.32Therapeutics and Clinical Risk Management 2011:7
Table 1 Key outcome measures in patients with knee osteoarthritis
Outcome measure Patients aged ,65 years Patients aged $65 years
DSG (n = 301) Vehicle (n = 301) DSG (n = 189) Vehicle (n = 185)
Mean (SD) baseline wOMAC pain 12.3 (2.7) 12.3 (2.7) 12.1 (2.6) 11.8 (2.5)
LS mean change from baseline -5.8a -4.7 -5.3b -4.1b
Se 0.28 0.28 0.34 0.35
Percentage change from baseline 47.2 38.2 43.8 34.7
Mean (SD) baseline wOMAC function 40.2 (10.8) 40.5 (11.1) 40.3 (11.0) 38.8 (10.9)
LS mean change from baseline -17.9a -14.2 -15.5a -11.0
Se 0.9 0.9 1.1 1.1
Percentage change from baseline 44.5 35.1 38.5 28.4
Mean (SD) baseline GRD 63.0 (19.5) 63.3 (18.8) 61.8 (18.9) 61.4 (21.9)
LS mean change from baseline -29.5c -23.8 -23.8 -18.7
Se 1.6 1.7 2.0 2.1
Percentage change from baseline 46.8 37.6 38.5 30.4
Mean (SD) baseline POM 75.3 (11.7) 74.7 (12.2) 74.1 (11.8) 74.7 (12.0)
LS mean POM -37.3d -29.0 -33.7b -26.4
Se 1.8 1.8 2.2 2.2
Percentage change from baseline 49.5 38.8 45.5 35.3
Notes: aP , 0.01 for diclofenac sodium 1% gel vs vehicle; bP = 0.02 for diclofenac sodium 1% gel vs vehicle; cP = 0.01 for diclofenac sodium 1% gel vs vehicle; dP , 0.001 for 
diclofenac sodium 1% gel vs vehicle. 
Abbreviations: DSG, diclofenac sodium 1% gel; GRD, global rating of disease; LS, least squares; POM, pain on movement; SD, standard deviation; Se, standard error of the 
mean; wOMAC, western Ontario and McMaster Universities Osteoarthritis index.
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Efficacy of topical NSAIDs in elderly 
patients
The efficacy of DSG and vehicle gel for the treatment 
of knee osteoarthritis was compared in older patients 
(aged $ 65 years; DSG, n = 189; vehicle, n = 185) vs younger 
patients (aged ,65 years; DSG, n = 301; vehicle, n = 301) 
in a pooled analysis of three 12-week, randomized, double-
blind trials. Efficacy measures included the Western Ontario 
and McMaster Universities Osteoarthritis Index pain and 
physical function subscales, a global rating of disease, and 
pain on movement.
In older patients, improvements from baseline in all out-
come measures ranged from 39% to 46% with DSG and from 
28% to 35% with vehicle; in younger patients, improvements 
ranged from 45% to 50% with DSG and 35% to 39% with 
vehicle (Table 1). Improvements with DSG were significant 
for pain, function, and pain on movement in older patients 
and for all outcome measures in younger patients.
Notably, topical diclofenac is indicated as monotherapy 
for patients with osteoarthritis limited to a few superficial 
joints. However, some guidelines recommend using topical 
NSAIDs as an adjunctive therapy for osteoarthritis pain.5,12 
A recent study of D-DMSO included a treatment arm that 
modeled adjunctive use of topical NSAIDs for knee osteoar-
thritis pain.19 In this 12-week, five-arm, 775-patient trial, an 
oral diclofenac/topical D-DMSO combination was not more 
effective than oral diclofenac alone, suggesting that topical 
NSAIDs cannot effectively augment the analgesia provided 
by oral NSAIDs. However, no significant differences between 
D-DMSO alone and oral diclofenac alone occurred for any 
efficacy outcome, indicating that oral diclofenac offered no 
advantage over topical diclofenac for knee osteoarthritis. 
Therefore, the decision to use a topical vs an oral NSAID 
should be based on the location and extent of the osteoar-
thritis, not the severity of the pain. For osteoarthritis pain 
localized to a few superficial joints, oral NSAIDs offer no 
advantage over topical NSAIDs.
Tolerability of topical NSAIDs in 
elderly patients
Pooled data from five randomized controlled trials assessed 
DSG safety in older ($65 years) and younger (,65 years) 
patients, ie, three trials in patients with knee osteoarthritis 
(n = 1426) and two trials in patients with hand osteoarthri-
tis (n = 783).33 Irrespective of osteoarthritis type or age, 
adverse events were more frequent on DSG than on vehicle 
(Table 2), mostly owing to a higher rate of application site 
adverse events with DSG. Gastrointestinal and other systemic 
adverse events occurred with similar frequency in the two 
treatment groups. In knee osteoarthritis trials, three patients 
applying DSG ($65 years, n = 1; ,65 years, n = 2) and two 
applying vehicle (one patient per age group) experienced 
treatment-related gastrointestinal adverse events. In the hand 
osteoarthritis trials, two DSG-treated patients (one per age Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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group) and one vehicle-treated patient (,65 years) expe-
rienced treatment-related gastrointestinal adverse events. 
Cardiovascular, renal, and hepatic adverse events occurred 
with similar frequency on DSG and vehicle in older and 
younger patients. Only one serious adverse event, ie, deep 
vein thrombosis with pulmonary embolism in an 80-year-old 
woman with hypertension and type 2 diabetes, was deemed 
potentially related to treatment. The adverse event was con-
sidered mild in severity and was managed successfully with 
warfarin and heparin.
In the 12-week, five-arm, 775-patient trial of D-DMSO,19 
the combination of oral diclofenac with D-DMSO was 
not associated with an increased incidence of systemic 
adverse events compared with oral diclofenac alone. In 
particular, gastrointestinal adverse events were reported 
in 23.8% of patients treated with oral diclofenac alone 
and 25.7% of those receiving oral and topical diclofenac 
concurrently. Patients treated with D-DMSO alone had a 
lower incidence of gastrointestinal adverse events than did 
those assigned to placebo (6.5% vs 9.6%). These results 
suggest that D-DMSO acted locally, producing systemic 
cyclo-oxygenase inhibition insufficient for a clinically 
meaningful increase in the   cyclo-oxygenase inhibition 
achieved with the oral NSAID alone. Although the results 
of this trial were not stratified by age, the mean ± standard 
deviation ages by treatment group were 61.7 ± 9.8 years in 
the D-DMSO group, 62 ± 10.5 years in the oral diclofenac 
group, and 60.6 ± 10.0 years in the group taking oral and 
topical diclofenac concurrently. This indicates that the study 
population included numerous seniors. No serious adverse 
event was reported in any patient treated with D-DMSO, 
regardless of age.
Table  2  Total  and  most  frequent  adverse  events  ($3%  of  randomized  patients  in  any  group)  in  patients  with  knee  or  hand 
osteoarthritis
Adverse event, n (%) Patients with knee osteoarthritis Patients with hand osteoarthritis
Aged , 65 years Aged $ 65 years Aged , 65 years Aged $ 65 years
DSG  
(n = 447)
Vehicle  
(n = 441)
DSG  
(n = 274)
Vehicle  
(n = 264)
DSG  
(n = 215)
Vehicle  
(n = 215)
DSG  
(n = 185)
Vehicle  
(n = 168)
Any Ae 253 (56.6) 224 (50.8) 153 (55.8) 116 (43.9) 84 (39.1) 81 (37.7) 79 (42.7) 58 (34.5)
Serious Aesa 5 (1.1) 2 (0.5) 7 (2.6) 3 (1.1) 2 (0.9) 2 (0.9) 2 (1.1) 2 (1.2)
Deathsb 0 0 1 (0.4) 0 0 0 0 0
Gastrointestinal Aes 23 (5.1) 20 (4.5) 11 (4.0) 11 (4.2) 10 (4.7) 10 (4.7) 13 (7.0) 7 (4.2)
Application site Aes 25 (5.6) 8 (1.8) 24 (8.8) 3 (1.1) 7 (3.3) 4 (1.9) 11 (5.9) 4 (2.4)
Cv Aes 9 (2.0) 5 (1.1) 5 (1.8) 3 (1.1) 1 (0.5) 2 (0.9) 1 (0.5) 1 (0.6)
Angina pectoris 1 (0.2) 1 (0.2) 0 0 0 0 0 0
Atrial fibrillation 1 (0.2) 0 0 0 0 0 0 0
Coronary stent surgery 0 0 0 0 0 0 0 1 (0.6)
Deep vein thrombosisa 0 0 1 (0.4) 0 0 0 0 0
Orthostatic hypotension 0 0 1 (0.4) 0 0 0 0 0
Palpitations 1 (0.2) 0 0 1 (0.4) 0 0 0 0
Sinus arrhythmia 1 (0.2) 0 0 0 0 0 0 0
Supraventricular extrasystoles 0 1 (0.2) 0 0 0 0 0 0
Tachycardia 1 (0.2) 0 0 0 0 0 0 0
Ventricular fibrillationb 0 0 1 (0.4) 0 0 0 0 0
worsening hypertension 6 (1.3) 3 (0.7) 2 (0.7) 2 (0.8) 1 (0.5) 2 (0.9) 1 (0.5) 0
Renal Aesc 2 (0.4) 1 (0.2) 3 (1.1) 1 (0.4) 0 1 (0.5) 0 0
Blood creatinine increased 0 1 (0.2) 2 (0.7) 1 (0.4) 0 0 0 0
Diabetic nephropathy 0 0 0 0 0 1 (0.5) 0 0
Hematuria 1 (0.2) 0 0 0 0 0 0 0
Nephrolithiasis 1 (0.2) 0 0 0 0 0 0 0
Pollakiuria 0 0 1 (0.4) 0 0 0 0 0
Hepatic Aes 1 (0.2) 3 (0.7) 1 (0.4) 3 (1.2) 1 (0.5) 0 0 2 (1.2)
elevated alanine aminotransferase 1 (0.2) 3 (0.7) 0 1 (0.4) 1 (0.5) 0 0 1 (0.6)
elevated aspartate aminotransferase 1 (0.2) 3 (0.7) 0 0 0 0 0 1 (0.6)
elevated gamma-glutamyltransferase 1 (0.2) 0 1 (0.4) 2 (0.8) 0 0 0 1 (0.6)
Notes: aOne serious, possibly treatment-related Cv Ae (deep vein thrombosis and pulmonary embolism) occurred in an 80-year-old woman with hypertension and T2DM. 
No other serious Ae or Cv Ae was considered treatment-related; bone fatal, nontreatment-related CV AE (ventricular fibrillation) occurred in a 76-year-old man without 
T2DM, hypertension, or Cv disease; cTreatment-related blood creatinine increases occurred in one patient who received DSG and two who received vehicle. No other 
renal Ae was treatment-related.
Abbreviations: Ae, adverse event; Cv, cardiovascular; DSG, diclofenac sodium 1% gel; T2DM, type 2 diabetes mellitus.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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A 1-year, open-label trial assessed the long-term safety of 
DSG in 578 patients with knee osteoarthritis;34 291 patients 
completed one of the 12-week trials described earlier, and 
292 were naive to topical NSAID therapy. The study included 
208 (36.0%) patients aged 60–70 years, 113 (19.6%) patients 
aged 70–80 years, and 13 (2.2%) patients aged .80 years. 
Twenty-nine patients experienced a total of 36 serious 
adverse events. One serious adverse event was considered 
potentially treatment-related, ie, deep vein thrombosis with 
pulmonary embolism (described above), which occurred in 
one patient during the randomized controlled trial preceding 
this open-label study. Similarly, a 1-year, open-label study 
of D-DMSO assessed its long-term safety in patients who 
completed the five-arm trial described earlier (n = 221) as 
well as newly enrolled patients (n = 572).35 The mean age 
was 62.5 ± 10.1 years, indicating that the population included 
numerous seniors. The tolerability of D-DMSO during 
long-term therapy was similar to that seen in the short-term 
studies, with application site reactions constituting the most 
common adverse events and systemic adverse events occur-
ring infrequently.
Thus, short-term (12-week) data on DSG and D-DMSO 
show good safety and tolerability in older patients, and 
open-label study data provide preliminary evidence of 
long-term safety. Nonetheless, few long-term safety data in 
older patients exist, particularly for patients aged .80 years. 
Until such data are available, topical NSAIDs should be 
avoided in patients with absolute contraindications to oral 
NSAIDs and used with caution in patients with relative 
contraindications.
Unique needs of long-term  
care patients
A correlation exists between inadequately controlled pain and 
impairment of activities of daily living and need for extensive 
supervision.36 For patients with osteoarthritis residing in 
long-term care facilities, symptomatic osteoarthritis of the 
hand and knee complicate care. Hand osteoarthritis is asso-
ciated with feelings of dependence and embarrassment and 
the inability to carry out normal tasks.37 Knee osteoarthritis 
is associated with impaired mobility and increased risk of 
falls resulting in fractures.38 Unfortunately, the structural 
changes that impair function in osteoarthritis are not reversed 
or modified by current pharmacologic therapies, and many 
long-term care patients are medically unfit for orthopedic 
surgical interventions.
Despite having no disease-modifying mechanism of 
action, topical NSAIDs improve physical function and 
reduce joint stiffness in knee16,18,39 and hand20 osteoarthritis. 
Post hoc analyses of randomized controlled trials of topical 
NSAIDs in knee40 and hand41 osteoarthritis show a correlation 
between pain relief and improvements in physical function, 
regardless of active vs placebo treatment. Evidently, some 
loss of function in hand and knee osteoarthritis results from 
voluntary or involuntary restriction of movement in response 
to pain, not structural limitations. Thus, any pain reduction 
may improve function.
Assessing and effectively treating pain in long-term care 
patients is challenging. Elderly patients may be reluctant 
to report pain, believing that recognition of pain is a sign 
of weakness, progression of illness, or impending death.42 
Patients with (vs without) cognitive impairment are much 
less likely to report chronic pain, even if pain is expected, 
and are less likely to receive analgesics.43 Approximately half 
of nursing home patients receive analgesics as needed rather 
than regularly,43 increasing the likelihood of undertreatment 
in patients unable to report pain. However, even patients 
who report pain may be unable to comply with prescribed 
treatment regimens. Up to 50% of nursing home patients 
experience dysphagia, complicating treatment with oral 
medications.44 Taking of multiple medications, which is 
common in older patients, is associated with poor adher-
ence45 and drug interactions.28 Using topical NSAIDs allows 
for regular, scheduled administration of effective analgesia 
without increasing pill counts and despite swallowing ability. 
In clinical trials of topical NSAID therapy, patient adherence 
to treatment ranged from .75% to 94%.16–20
Easy administration of a topical formulation is beneficial 
in the long-term care setting. Application of a gel or solution 
by the caregiver is less disruptive than giving a pill and does 
not require observation or assurance of ingestion. Further, 
although not widely studied, treatment incorporating physical 
contact provides comfort, reduces anxiety, and promotes a 
sense of well-being in nursing home residents.46 However, 
the value of topical administration toward adherence and 
psychologic benefit may be somewhat offset by the time that 
nursing home staff must spend applying topical products.
Conclusion
Given concerns about the safety of NSAIDs, particularly in 
older patients, the availability of topical diclofenac formula-
tions in the US offers long-term care providers a valuable 
means of limiting NSAID exposure in patients with osteoar-
thritis in a few superficial joints. The topical formulation may 
also facilitate administration of medication in a long-term 
care population.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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